Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.

Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antihypertensive Agents
Blood Pressure Determination
Dose-Response Relationship, Drug
Drug Administration Schedule
Echocardiography, Doppler
Female
Follow-Up Studies
Humans
Hypertension
Hypertrophy, Left Ventricular
Imaging, Three-Dimensional
Losartan
Magnetic Resonance Imaging
Male
Middle Aged
Prospective Studies
Reference Values
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
Treatment Outcome

authors with profiles

David Calhoun